Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting

T-cell acute lymphoblastic leukemia (T-ALL) occurs in approximately 25–30% of adult ALL. Currently, treatment approaches for adult patients with T-ALL remain quite limited, with intensive multiagent chemotherapy serving as the backbone; however, the cure rate remains unsatisfactory. Thus, the discov...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jieyu, Zhu, Hong-Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007722/
https://www.ncbi.nlm.nih.gov/pubmed/36906578
http://dx.doi.org/10.1186/s40164-023-00384-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007722/
https://www.ncbi.nlm.nih.gov/pubmed/36906578
http://dx.doi.org/10.1186/s40164-023-00384-4

Ejemplares similares